23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
Steven Stack will be the association's youngest president when he takes office in 2015.
Lonnel Coats is leaving after 18 years with the company.
Victor Dzau's six-year term starts July 1.
Former Associate Commissioner for the Office of External Affairs at the U.S. Food and Drug Administration, Virginia Cox has re-joined 3D Communications.
Herve Hoppenot changed jobs overnight.
Erez Vigodman will be Teva's president and CEO as of February 11.
The company is rumored to have a name in mind, months after a contentious break with then-CEO Jeremy Levin.
The company's new president and possible CEO is expected to have significant latitude to change things.
The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.
GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues
Shire expands its pipeline yet again, AthenaHealth stretches its HCP-patient reach, FDA delays GSK's bird-flu vaccine, Novartis wins approval for cystic fibrosis inhaler
Former Pfizer chieftain Hank McKinnell is taking the reins at stock scandal-plagued Optimer—perchance to sell it to Pfizer?
The latest executive change has a touch of deja-vu: Novartis vet Jorg Reinhardt is returning from a stint at Bayer.The company also said it expects 2013 sales to be flat, but sees growth in 2014 and 2015.
AstraZeneca jettisoned its global head of commercial operations and R&D chief, eliminating their roles and curtly suctioning off the company's second-highest layer of management.
FDA's Jane Axelrad is leaving the Office of Regulatory Policy to head the agency's compounding policy rethink.
Mark Iwicki, previously president and CEO of Sepracor, has signed on as chief executive officer with oncology-focused pipeline biopharma Blend Therapeutics.
Endo is on the hunt for a new President and CEO, Lundbeck lands a $50 million milestone payment and Lilly scales back a Phase III trial.
Teva names new president/CEO for Americas
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.